saphenamycin: from Streptomyces canarius; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 134184 |
| CHEBI ID | 32119 |
| SCHEMBL ID | 11190017 |
| MeSH ID | M0111567 |
| Synonym |
|---|
| nsc-336236 |
| mg 314-hf8 |
| nsc-361634 |
| nsc336236 |
| nsc361634 |
| 1-phenazinecarboxylic acid, 6-[1-[(2-hydroxy-6-methylbenzoyl)oxy]ethyl]- |
| 1-phenazinecarboxylic acid, 6-(1-((2-hydroxy-6-methylbenzoyl)oxy)ethyl)- |
| saphenamycin |
| 6-[1-(2-hydroxy-6-methylbenzoyl)oxyethyl]phenazine-1-carboxylic acid |
| CHEBI:32119 |
| SCHEMBL11190017 |
| 6-[1-(2-hydroxy-6-methyl-benzoyl)oxyethyl]phenazine-1-carboxylic acid |
| k9x7806v5b , |
| saphenamycin, (+/-)- |
| 634600-55-8 |
| unii-k9x7806v5b |
| racemic ssaphenamycin |
| (+/-)-saphenamycin |
| Q27114792 |
| 6-(1-((2-hydroxy-6-methylbenzoyl)oxy)ethyl)phenazine-1-carboxylic acid |
| 6-{1-[(2-hydroxy-6-methylbenzoyl)oxy]ethyl}phenazine-1-carboxylic acid |
| DTXSID301003193 |
| (+)-6-[1-[(2-hydroxy-6-methylbenzoyl)oxy]ethyl]-1-phenazinecarboxylic acid |
| AKOS040747467 |
Saphenamycin proved to be a potent antibiotic against fusidic acid and rifampicin resistant S.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Saphenamycin proved to be a potent antibiotic against fusidic acid and rifampicin resistant S." | ( First synthesis of racemic saphenamycin and its enantiomers. investigation of biological activity. Jørgensen, CG; Laursen, JB; Nielsen, J, 2003) | 1.34 |
| Class | Description |
|---|---|
| phenazines | Any organonitrogen heterocyclic compound based on a phenazine skeleton and derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.34) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||